Cash, Cash Equivalents and Marketable Securities

12 Months Ended

Dec. 31, 2021

Cash And Cash Equivalents [Abstract]

Cash, Cash Equivalents and Marketable Securities

4. Cash, Cash Equivalents and Marketable Securities

Cash, cash equivalents and marketable securities consisted of the following (in thousands):

	December 31, 2021
	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
Cash and cash equivalents:
Cash	$	44,499	$	—	$	—		$	44,499
Money market funds		117,023		—		—			117,023
Commercial paper		16,898		—		(1	)		16,897
Corporate debt securities		3,306				(1	)		3,305
Total cash and cash equivalents	$	181,726	$	—	$	(2	)	$	181,724
Marketable securities:
Commercial paper	$	34,978	$	—	$	(10	)	$	34,968
U.S. government and agency securities		85,309		1		(88	)		85,222
Corporate debt securities		53,172		4		(38	)		53,138
Total marketable securities	$	173,459	$	5	$	(136	)	$	173,328

	December 31, 2020
	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
Cash and cash equivalents:
Cash	$	5,659	$	—	$	—		$	5,659
Money market funds		113,592		—		—			113,592
Certificate of deposit		157		—		—			157
Commercial paper		40,844		—		—			40,844
U.S. government and agency securities		27,498		—		—			27,498
Total cash and cash equivalents	$	187,750	$	—	$	—		$	187,750
Marketable securities:
Commercial paper	$	35,089	$	—	$	—		$	35,089
U.S. government and agency securities		26,026		6		(3	)		26,029
Corporate debt securities		1,504		—		—			1,504
Total marketable securities	$	62,619	$	6	$	(3	)	$	62,622

The amortized cost and estimated fair value of our available-for-sale marketable securities by contractual maturity are summarized below as of December 31, 2021 (in thousands):

	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
Mature in one year or less	$	105,184	$	1	$	(72	)	$	105,113
Mature after one year through two years		68,275		4		(64	)		68,215
Total available-for-sale marketable securities	$	173,459	$	5	$	(136	)	$	173,328

None of our marketable securities were in a continuous unrealized loss position as of December 31, 2021. We review the individual securities in our portfolio to determine whether a decline in a security’s fair value below the amortized cost basis is other-than-temporary. We determined that as of December 31, 2021 and 2020, there were no investments in our portfolio that were other-than-temporarily impaired.